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Background: Gastrodia elata Blume (GEB), commonly used medicinal herb, has been reported as a promising candidate
for neurodegenerative diseases such as Parkinson’s disease. The dopamine precursor, L-3,4-dihydroxyphenylalanine
(L-DOPA), is the gold-standard drug for Parkinson’s disease, but long-term treatment results in the L-dopa-induced
dyskinesia (LID). This study was undertaken to examine the beneficial effects of GEB on L-DOPA induced dyskinesia
in 6-hydroxydopamine (6-OHDA)-induced experimental Parkinsonism.
Methods: We tested the effects of GEB on LID in 6-hydroxydopamine hydrochloride-hemiparkinsonian mice. To
analyze the dyskinetic anomalies, we measured abnormal involuntary movement (AIM). Immunohistological
analyses of pERK and FosB expressions in the striatum are performed to explore the mechanism of GEB on LID.
Results: The finding of this study demonstrated that GEB (200, 400 and 800 mg/kg) alleviated L-dopa induced
AIMs in a dose-dependent manner. In each integrative AIM subtype analysis, we also found that the GEB (400 and
800 mg/kg) treatment decreased L-DOPA-induced axial, limb, orolingual, and locomotive AIMs compared to the
LID group. In addition, GEB normalized the abnormal LID-induced increase of pERK1/2 and FosB, the immediate
early genes of LID in the striatum.
Conclusions: In conclusion, our results provide a novel insight into the pharmacological actions of GEB that could
have a benefit for PD patients through the reduction of LID.
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Parkinson’s disease (PD), which afflicts 1-2% of the popu-
lation over 65 years of age, is the second most common
neurodegenerative disorder. PD arises from the striatal de-
pletion of dopamine (DA) [1-3]. This characteristic has led
to the use of dopamine agonists, including 3,4-dihydroxy-
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unless otherwise stated.enhance synaptic DA transmission [4,5]. Although dopa-
minergic drugs are highly effective agents for the symptom-
atic treatment of PD [4-8], patients who have undergone
long-term L-DOPA administration experience adverse ef-
fects, including motor fluctuations and dyskinesia [9-11].
Increasing reports regarding these adverse effects of L-
DOPA have led to a backlash among some PD patients
who fear these side effects more than they value the thera-
peutic benefit of L-DOPA treatment [12]. Dyskinesis is a
common complication of L-DOPA treatment with an inci-
dence of approximately 10% of PD patients per year. Some
40-50% of PD patients who undergo L-DOPA treatment
for 4–6 years developed dyskinesia, and the incidence in-
creased to 90% in patients treated for 10 years [6,13,14].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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esia (LID) in PD is mediated by alterations in basal ganglia
activity [15,16]. It is believed that chronic treatment with
L-DOPA (with its short half-life, requirement for pulsatile
delivery to the brain and subsequent stimulation of post-
synaptic striatal neurons with dopamine) is a key factor
leading to the induction of dyskinesia in PD patients [2,17].
Gastrodia elata Blume (GEB) belongs to the Orchidaceae
family and is one of the most popular herbs used by pa-
tients across different clinical settings in Asia. It has been
used in the treatment of many conditions, such as convul-
sion, ischemia, dementia, tremors, and vertigo [18-20]. A
number of studies have been conducted to investigate pos-
sible effects of GEB on brain function. For example, GEB
has been found to inhibit glutamate-induced apoptosis in
neuroblastoma cells [21], kainite-induced neuronal dam-
age [22], and MPP + −induced cytotoxicity in SH-SY5Y
cells [23]. It was also found to protect against neuronal cell
damage following transient global brain ischemia [24].
GEB contains various biologically active components [25]
that may improve neuronal cell viability through inhibition
of apoptosis [24,26]. This may also be the mechanism by
which GEB treatment protects neuronal cells damaged by
transient brain ischemia [26]. While many studies have
shown the potential utility of GEB in PD treatment, no ex-
periments have examined the effects of GEB on the ameli-
oration of adverse L-DOPA effects in PD models.
In this study, we used a paradigm which is representa-
tive of clinical L-DOPA use: intermittent delivery of a
constant dose of L-DOPA to mice unilaterally lesioned
with 6-OHDA. To assess the value of GBE in PD, we ini-
tially investigated the anti-dyskinetic effects of the GEB
extract in an LID mouse model.
Methods
Animals
Nine-week-old male C57Bl/6 mice (Central Lab. Animal
Inc., Seoul, Republic of Korea), weighing 23–26 g each,
were used in all experiments. The animals were housed
under a 12 h light/12 h dark cycle with ad libitum access
to food and water.
All experiments were approved by the Kyung Hee Uni-
versity Animal Care Committee for animal welfare
[KHUASP(SE)-09-046] and maintained in strict accord-
ance with Guidelines of the NIH and Korean Academy of
Medical Sciences for animal care and use of laboratory an-
imals at Kyung Hee University, Republic of Korea.
Unilateral 6-OHDA lesion
Mice were anesthetized with a mixture of tiletamine and
zolazepam (30 mg/kg; Zoletil 50, Virbac, France) and xyla-
zine (10 mg/kg; Rompun, Bayer Korea, Republic of Korea)
in physiological saline and mounted in a stereotaxic frame
with a mouse adaptor (Stoelting Co., Wood Dale, IL,USA). A solution of 6-OHDA-HCl (3.0 μg/μL) was pre-
pared in saline containing 0.02% ascorbic acid (Sigma-
Aldrich, St. Louis, MO, USA). Each mouse received two
unilateral injections of 6-OHDA-HCl (2 μL) into the right
striatum, as previously described, according to the following
coordinates: (1) AP +1.0 mm, ML −2.1 mm, DV −3.2 mm;
and (2) AP +0.3 mm, ML −2.3 mm, DV −3.2 mm (total 2
sites × 2 μL). For control mice, two intrastriatal injections
of saline were given at the same coordinates. Each injection
was performed at a rate of 0.5 μL/min using a glass capil-
lary with an outer diameter of 50 μm attached to a
Hamilton syringe. After the injection, the capillary was left
in place for an additional 3 min before being retracted
slowly [13]. Mice were allowed to recover from surgery for
15 days in their home cages prior to the start of any experi-
mental procedure.
Drugs and experimental design
GEB (Product #: 5413, Lot#: 142311) manufactured by Sunten
Pharmaceutical (Taipei, Taiwan) have been approved as
herbal medicines by Taiwan Food and Drug Adminstration
(TFDA). TFDA accepted GEB manufacturing process, effi-
cacy and safety assurance, quality control method. Extract
of GEB was deposited by Kyung Hee University herbarium
(Deposit #: KHH-G-0028). After a period of recovery from
the 6-OHDA lesions, mice were divided randomly into ex-
perimental groups and administered L-DOPA (20 mg/kg,
intraperitoneally) and daily drug treatments for 10 days.
Daily drug treatments consisted of oral administration of
200, 400, and 800 mg/kg of the GEB extract or 40 mg/kg of
amantadine (AMTD; Sigma-Aldrich, St. Louis, MO, USA).
L-DOPA was freshly dissolved in physiological saline and
combined with 12 mg/kg of benserazide (Sigma-Aldrich,
St. Louis, MO, USA), as previously described [27]. The
GEB extract and AMTD were dissolved in distilled water
by sonication in an ultrasonic water bath for 3 h. The GEB
extract was administered at 120 min prior to the L-DOPA
injection and AMTD was administered at 100 min prior.
These experimental protocols have been reported previ-
ously to lead to the development of LID and maximal anti-
dyskinetic potency of AMTD in the same mouse model
used in this study [13]. The experimental procedure is also
shown in Figure 1. The experimental groups were as
follows (n = 7-10 in each group): (1) 6-OHDA group, 6-
OHDA+ vehicle + vehicle; (2) L-DOPA group, 6-OHDA+L-
DOPA+ vehicle; (3) GEB200 group, 6-OHDA+L-DOPA+
GEB extract 200 mg/kg; (4) GEB400 group, 6-OHDA+L-
DOPA + GEB extract 400 mg/kg; (5) GEB800 group, 6-
OHDA + L-DOPA + GEB extract 800 mg/kg; and (6)
AMTD group, 6-OHDA + L-DOPA + AMTD 40 mg/kg.
Abnormal involuntary movement (AIM) score
We used an AIM assessment method to examine LID in
the mice, as previously described [27-30]. To quantify
Figure 1 Schematic representation of experimental design. Numerals within the time course arrow denote the number of days after the start
of chronic treatment with L-DOPA, GEB (200, 400, and 800 mg/kg), AMTD (40 mg/kg), or vehicle. Contralateral turning behavior was tested 14 days
later, after apomorphine injection. Three weeks after the introduction of 6-OHDA lesions, mice were administered with L-DOPA, GEB, or AMTD
daily for 10 days. AIMs scores were assessed on days 2, 5, and 9 after initial treatment.
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blinded observer to assess abnormal behaviours. The ob-
servations were made individually every 20 min from 20
to 140 min after the injection of L-dopa or vehicle. Over
the course of the experiment, AIM scores of the mice
were evaluated at 2, 5, and 9 days after the first L-DOPA
injection. AIM scores were classified based on topographic
distribution into four different subtypes: (1) axial AIM, de-
fined as contralateral twisted posturing of the upper body
and neck; (2) limb AIM, indicated by repetitive, rhythmic
jerky movements or dystonic posturing of the forelimb on
the side contralateral to the lesion; (3) orolingual AIM,
characterized by orofacial muscle twitching, empty masti-
catory movements and contralateral tongue protrusion;
and (4) locomotive AIM, defined as increased locomotion
with contralateral side bias. Each of these four subtypes
was scored on a severity scale from 0 to 4 (0, absent; 1,
present for less than half of the observation time; 2,
present for more than half of the observation time; 3, con-
tinually present but suppressible by outer stimuli; 4, con-
tinually present and not suppressible). A total AIMS score
was calculated for each mouse by combining each of the
four individual dyskinesia scores. The assessments were
performed in a blind manner.
Western blotting
Within 30 min after the last L-DOPA injection, the stri-
atum was quickly dissected and lysed in lysis buffer
(2.5 M NaCl, 1 M TrisHCl (pH 7.5), 0.5 M sodium di-
phosphate, 1 M NaF, 0.5 M EDTA, 0.5 M Na3VO4, and
10% Triton X-100). Lysates were cleared by centrifuga-
tion and the protein concentration was determined.
Some 20 μg of total protein was separated by 10% (w/v)
SDS-PAGE and transferred to a PVDF membrane. The
membrane was shaken in Tris-buffered saline containing
0.1% Tween-20 for washing. The membrane was shaken
for 1 h at room temperature in 5% (w/v) skim milk to
block nonspecific signals and incubated overnight with
primary antibodies at 4°C. The following primary anti-
bodies were used in this study: β-actin (Santa Cruz Bio-
technology Inc., Dallas, TX, USA), Phospho-ERK1/2,ERK1/2, and FosB (Cell Signaling Technology, Danvers,
MA, USA). The membrane was shaken for 60 min at
room temperature in the presence of a horseradish
peroxidase-conjugated goat anti-rabbit and anti-mouse
secondary antibody (Pierce Biotechnology, Rockford, IL,
USA) and visualized with a chemiluminescence kit (West
Pico; Pierce Biotechnology, Rockford, IL, USA). Band in-
tensities of the detected proteins were measured by
densitometry.High performance liquid chromatography (HPLC) analysis
of drug
We performed HPLC analysis to qualify the GEB extract
used in this study. Samples of the GEB extract (1 mg)
were dissolved in distilled water (1 mL). Samples were
filtered and 10 μL of sample solution injected into the
HPLC system (1260 infinity HPLC system, Agilent Tech-
nologies, Palo Alto, CA, USA) with a UV detector. Sam-
ples were analyzed on an Atlantis C18 analytical column
(150 × 3.0 mm, 5 μm; Waters, Milford, MA, USA). The
mobile phase consisted of distilled water (solvent A) and
methanol (solvent B). The flow rate was 1 mL/min and
gradient elution was used. The gradient elution program
was as follows: initially 5% (v/v) solvent B, which was
linearly increased to 70% (v/v) at 25 min and maintained
up to 28 min. At 29 min, the composition of the mobile
phase was returned to initial conditions, which were
maintained for 11 min for column re-equilibration. The
eluent was monitored at 221 nm.Statistical analysis
All procedures, assessments, and analyses were per-
formed blindly to minimize observer bias. GraphPad
Prism version 5 (GraphPad Software Inc., San Diego,
CA, USA) was used for statistical analysis. All data are
expressed as the mean ± SEM. Comparisons of total
AIM scores and of biochemical or protein assays among
groups were analyzed by a one-way ANOVA followed by
a Bonferroni’s post-hoc test. In all of the analyses, differ-
ences were considered statistically significant at P < 0.05.
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Component analysis of the GEB extract
Gastrodin is known to be the one of main biologically
active components of GEB. Thus, we sought to detect
the main component of the GEB extract by HPLC ana-
lysis. Gastrodin was found at 5.6 min in the HPLC chro-
matogram. The content of gastrodin in the GEB extract
was determined to be 0.237 ± 0.002%. A representative
HPLC chromatogram of the Gastrodia elata Blume ex-
tract sample is shown in Figure 2.
Effect of the GEB extract on L-DOPA-induced total AIMS
score
We found that various doses of the GEB extract and
AMTD significantly lowered integrated total AIMs scores
compared to the LID group on days 5 and 9 (Figure 3).
On day 2, L-DOPA-induced AIMs scores were high and
no significant differences were found between groups
(40.4 ± 3.1, 39.1 ± 2.3, 35.0 ± 4.7, 23.9 ± 4.9, and 31.9 ± 5.6;
the LID, GEB200, GEB400, GEB800, and AMTD groups,
respectively; Figure 3A). On day 5, the L-DOPA group also
exhibited high AIMs scores (36.7 ± 3.9), while all other
treatment groups showed significantly lower AIMs scores
compared to the LID group (29.9 ± 4.2, 28.3 ± 6.7, 15.1 ±
3.8, and 27.6 ± 5.1; the GEB200, GEB400, GEB800, and
AMTD groups, respectively; F6,41 = 26.91, P < 0.0001;
Figure 3B). The differences between AIMs scores
became more pronounced on day 9 (34.3 ± 3.7; LID,
22.1 ± 3.6, 19.0 ± 3.7, 11.1 ± 1.7, and 18.7 ± 3.0; the
GEB200, GEB400, GEB800, and AMTD groups, respect-
ively; F6,41 = 31.54, P < 0.0001). A time point comparison
between days 5 and 9 showed a significant decrease in
total AIMs scores in the GEB800 group compared to
the LID group (Figure 3D, E, and F).
Effect of the GEB extract on four subtypes of AIM score
induced by L-DOPA
In each integrative AIM subtype analysis, we found that
the GEB400, GEB800, and AMTD groups showed de-
creased L-DOPA-induced axial, limb, orolingual, andFigure 2 A representative chromatogram for standardization of the G
retention time; the Y-axis shows UV absorbance. Arrow indicates peak of glocomotive AIMs compared to the LID group on day 9
(Figure 4).
Effects of the GEB extract on LID-induced abnormal
increase of phospho-ERK1/2 and FosB
After the experiment, striatal tissues of the mice were
prepared for protein analysis. Levels of phospho-ERK1/2
and FosB in the striatum were examined. The phosphor-
ylation ratio of ERK1/2 was increased significantly in the
striata of mice in L-DOPA group and was found to be
224% of the control (P < 0.01, compared to 6-OHDA
control group). However, in the GEB200, GEB400, and
GEB800 groups ERK1/2 phosphorylation was normal-
ized to 171%, 142%, and 117% of the control, respect-
ively (P > 0.05, P < 0.05, and P < 0.01). The AMTD group
showed reduced ERK1/2 phosphorylation at approxi-
mately 162% of the control (Figure 5A).
FosB levels in the striata of mice in the L-DOPA group
were significantly higher than in those of the 6-OHDA
group (100% vs. 167% of control, P < 0.05). However, the
GEB200, GEB400, and GEB800 groups showed decreased
FosB levels at 128%, 115%, and 108% of the control, re-
spectively (P > 0.05, P > 0.05, and P < 0.05). The AMTD
group exhibited normalized FosB expression at 136% of
control (Figure 5B).
Discussion
Treatment with L-DOPA can lead to great enhancements
in motor function for PD patients, but it also has serious
adverse effects. Thus, researchers have sought to find novel
therapies that mitigate the adverse effects of L-DOPA while
enhancing its benefits. In the present study, we show that
the GEB extract alleviates LID in a 6-OHDA-induced
hemi-Parkinsonian mouse model. We have investigated its
possible mechanism of action through the inhibition of
ERK1/2 and FosB, which are abnormally activated due to
chronic L-DOPA treatment. The GEB extract showed sig-
nificant alleviation of dyskinesia in comparison with the
anti-dyskinetic effect of AMTD, a drug used in the treat-
ment of both PD and LID.astrodia elata Blume (GEB) extract sample. The X-axis shows
astrodin.
Figure 3 Effect of the GEB extract on L-DOPA-induced abnormal involuntary movements (AIMs) in a PD mouse model bearing 6-OHDA
lesions. (A-C) Total AIMs were scored every 20 min over a 140 min period following L-DOPA injection. The integrated total AIMs scores on days
2 (A), 5 (B), and 9 (C) are shown. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the LID group. (D-F) The integrated temporal profiles of
total AIMs scores on days 2 (D), 5 (E), and 9 (F) of the LID and LID + GEB800 treated group are shown. *P < 0.05 and **P < 0.01 compared with
the LID group.
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alleviation of LID in the PD mice model. GEB is used in
a traditional Korean medicine for the treatment of abnor-
mal activation in neuronal disorders, such as ischemia, de-
mentia, and tremors. Previous in vitro and animal studies
have described the effects of GEB in various neurologicalFigure 4 The effect of GEB extract treatment on each subtype of axia
induced by L-DOPA in a PD mouse model bearing 6-OHDA lesions. (A
AIM scores were measured on days 2, 5, and 9 after the initial L-DOPA inje
L-DOPA administration and were then integrated. *P < 0.05 and **P < 0.01diseases. However, this is the first study to show that GEB
exerts an anti-dyskinetic effect in an LID mouse model.
Moreover, high doses of GEB (800 mg/kg) attenuated dys-
kinesia more effectively than did the marketed drug aman-
tadine. Next, we analyzed the components of GEB to
elucidate the mechanism behind this beneficial effect.l, limb, and orolingual abnormal involuntary movement (AIM)
) Axial AIM, (B) limb AIM, (C) orolingual AIM, and (D) locomotive
ction. AIM scores were assessed every 20 min over 140 min following
compared with the LID group.
Figure 5 Protein analysis of ERK1/2 phosphorylation and FosB
expression in striatal tissue. Protein levels were evaluated by
western blotting the striatal extracts from each group of mice.
(A, B) Phospho-ERK1/2 (A) and FosB (B) signals were observed in
the ipsilateral sides of striata. Representative bar graph showing
optical densities from the blotting experiments. *P < 0.05 and
**P < 0.01 compared with the 6-OHDA control (Cont) group.
#P < 0.05 and ##P < 0.01 compared with the LID group.
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of LID have suggested that this condition arises from
sensitization of the neuronal dopamine D1-like receptor
and abnormal over-plasticity of the glutamate receptor,
which induce over-excited signaling in the basal ganglia
system. These authors reported that abnormal activation
of proteins in the postsynaptic pathway induces abnormaldyskinesia in LID animal models. The proteins implicated
in these studies include the dopamine- and cAMP-
regulated neuronal phosphoprotein of 32 kDa (DARPP-
32), ERK1/2, and transcription of the immediate early
gene FosB [27,31,32]. Moreover, the pharmacological
blockage of ERK1/2 signaling by a specific inhibitor or
transgenic deletion of DARPP-32 showed greatly de-
creased LID behavior in the same mouse model [27].
The phenolic glucoside gastrodin has been used in trad-
itional medicine for the treatment of various diseases and
considered as a main bioactive component of GEB in the
previous researches. Recent studies have shown gastrodin
to have efficacy against oxidative stress [33,34], inflamma-
tion [35-37], obesity [38], memory deficiency [39,40], and
Parkinson’s disease [23]. In these studies, the activity of
gastrodin was linked to modulation of various cellular sig-
naling pathways. Gastrodin was also effective in a mouse
model of Parkinson’s disease. Gastrodin has also been
found to inhibit abnormal NO synthase activity. It has also
been observed that gastrodin inhibits cytokine and MAPK
signaling expression induced by inflammation in BV-2
cells [41] and cardiomyocytes [42]. These studies showed
that gastrodin inhibited abnormal increases in ERK1/2,
JNK, and p38MAPK expression to reduce inflammation.
Although these results give limited insight into the mech-
anistic link between gastrodin and the inhibition of the
toxin-induced MAPK increase, they suggest the possibility
that gastrodin may regulate the MAPK proteins to miti-
gate the effects of toxins or pathogens. In this study, ab-
normally increased ERK 1/2 phosphorylation in the LID
mouse model was correlated with the increased expression
of FosB. FosB is an immediate early gene that requires
ERK activity for its transcription in the mouse striatum
[43]. Based on these results, we speculate that GEB atten-
uates MAPK signaling and FosB expression. This leads, in
turn, to normalized neuronal dopamine D1-like receptor
overplasticity and attenuated LID. However, this possibility
needs more evidence to draw a conclusion, and there is a
limitation to figure out exact mechanism of effects of GEB
from the results of this study. Further experiment would
be needed to investigate what exact mechanism is under-
lying the effects of GEB.
Conclusion
In conclusion, in this study, we found that the GEB ex-
tract alleviated LID, a set of adverse events associated
with L-DOPA administration. Furthermore, we suggest
that GEB induces the inhibition of MAPK signaling, in-
cluding ERK 1/2 phosphorylation and FosB expression.
This is the first study to show the beneficial effects of
the GEB extract against adverse events arising from
treatment with L-DOPA. These novel findings regarding
the effects and mechanism of the GEB extract on LID
represent an important step in the treatment of PD.
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